Healthpoint's cell-based therapy positive in Phase II trial in venous leg ulcers
This article was originally published in Scrip
Executive Summary
Healthpoint Biotherapeutics, an affiliate of DFB Pharmaceuticals of Forth Worth, Texas, has reported positive top-line results from a Phase IIb double-blind trial investigating the efficacy of its cell-based therapy, HP802-247, in venous leg ulcers over a 12-week period.